A BRIEF REVIEW ON NANO PARTICLES TO TREAT VARIOUS DISORDERS
Abstract
Nanoparticle innovation is quickly progressing and is utilized for a wire scope of utilizations in medication. Novel innovation in the nanomedicine field is required to create imaginative items as focused medication conveyance draws near. Directed medication conveyance of different medications for the treatement of malignant growth, AIDs and Brain issue is the essential examination region wherein nanomedicinehave a significant job and need. This audit gives a concise diagram of different issue in malignant growth, AIDs and mind issue of medication conveyance approaches alongside restrictions. This audit is worried about emergy focused on nanomedicines and multifunctional transporters fit for joining focused on sedate conveyance and imaging in the field of pharmaceutical applications.
Keywords:
Nanoparticle, nanomedicines, malignant growth, AIDs and Brain issue
Downloads
Download data is not yet available.
References
1. Wilkinson JM: Nanotechnology applications in medicine. Med. Device Technol. 14, 29–31(2003).
2. Roco MC: Nanotechnology: convergence with modern biology and medicine. Curr. Opin. Biotechnol. 14, 337–346 (2003).
3. Green JJ, Shi J, Chiu E et al.: Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug. Chem. 17, 1162–1169 (2006).
4. Torchilin VP: Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532–1555 (2006).
5. Kreuter J: Nanoparticles – a historical perspective. Int. J. Pharm. 331, 1–10 (2007).
6. Kreuter J: Nanoparticles as drug delivery systems. Encyclopedia Nanosci. Nanotechnol. 7, 161–180 (2004).
7. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318 (2001).
Presents the development of targeted and long-circulating nanomedicines.
8. Duguet E, Vasseur S, Mornet S et al.: Magnetic nanoparticles and their applications in medicine. Nanomed. 1, 157–168 (2006).
9. Torchilin VP: Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128–E147 (2007).
10. Singh S, Nalwa HS: Nanotechnology and health safety-toxicity and risk assessments of nanostructured materials on human health. J. Nanosci. Nanotechnol. 7, 3048–3070 (2007).
11. Allemann GE, Fessi H, Doelker E: Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22, 419–464 (2005).
12. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46, 149–168 (2001).
13. Hong S, Lerouell PR, Majoros IJ et al.: The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14, 107–115 (2007).
14. Brigger I, Dubernet C, Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631–651 (2002).
15. Steinhauser I, Spankuch B, Strebhardt K et al.: Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27, 4975–4983 (2006).
16. Tiefenauer LX, Kuhne G, Andres RY: Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 4, 347–352 (1993).
17. Hood JD, Bednarski M, Frausto R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002).
18. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phase display peptide libraries. Nature 380, 364–366 (1996).
19. Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542–546 (1997).
20. Shukla R, Thomas TP, Peters JL et al.: HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug. Chem. 17 1109–1115 (2006).
21. Sapra P, Allen TM: Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190–7194 (2002).
22. Cristoiu-Hapca A, Bossy-Nobs L, Buchegger F et al.: Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int. J Pharm. 331, 190–196 (2007).
23. Gartner S, Markovits P, Markovitz DM et al.: The role of mononuclear phagocytes in HTLV–III/LAV infection. Science 233, 215–219 (1986).
24. McCarthy TD, Karellas P, Henderson SA et al.: Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312–318 (2005).
25. Zhao H, Li J, Xi F et al.: Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA. FEBS Lett. 563, 241–245 (2004).
26. Begley DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharm. Ther. 104, 29–45 (2004).
27. Chen Y, Dalwadi G, Benson HAE: Drug delivery across the blood–brain barrier. Curr. Drug Deliv. 1, 361–376 (2004).
28. Allen DD, Lockman PR, Oyewumi MO et al.: Brain uptake of thiamine-coated nanoparticles. J.Control. Release 93, 271–282 (2003).
29. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37(1):13-25.
30. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32 (11):1959-72; PMID:22929442; http://dx.doi.org/ 10.1038/jcbfm.2012.126
31. Wagner, V., Dullaart, A., Bock, A.-K. & Zweck, A. The emerging nanomedicine landscape. Nat. Biotech. 24, 1211–1217 (2006).
32. Allemann E, Gurny R, Doelker E: Drug-loaded nanoparticles – preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39, 173–191 (1993).
33. Gref R, Minamitake Y, Peracchia MT et al.: Biodegradable long circulating nanospheres. Science 263, 1600–1603 (1994).
34. Labhasetwar V, Song C, Levy RJ: Nanoparticles drug delivery systems. Adv. Drug Deliv. Rev. 24, 63–85 (1997).
35. Swartz MA: The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50, 3–20 (2001).
36. Brannon-Peppas L: Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116, 1–9 (1995).
37. Castaldello A, Brocca-Cofano E, Voltan R40 et al.: DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 24, 5655–5669 (2006).
38. Mehnert W, Mader K: Solid lipid nanoparticles Production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165–196 (2001).
39. Venkateswarlu V, Manjunath K: Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95, 627–638 (2004).
40. Fahmy TM, Fong PM, Park Jet al.: Nanosystems for simultaneous imaging and drug delivery to T Cells. AAPS J. 9, E171–E180 (2007).
41. Li Y, Cheng Y, Xu T: Design, synthesis and potent pharmaceutical applications of glycodendrimers. Curr. Drug Discov. Technol. 4, 246–254 (2007).
42. Rosa Borges A, Schengrund CL: Dendrimers and antivirals: a review. Cur. Drug Targets Infect. Disord. 5, 247–254 (2005).
43. Wolinsky JB, Grinstaff MW: Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv.Drug Deliv. Rev. 60, 1037–1055 (2008).
44. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145–160 (2005).
45. Connor EE, Mwamuka J, Gole A et al.: Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1, 325–327 (2005).
46. Joshi HM, Bhumkar DR, Joshi K et al.: Gold nanoparticles as carrier for efficient transmucosal insulin delivery. Langmuir 22, 300–305 (2006).
47. Han G, Martin CT, Rotello VM: Stability of gold nanoparticle-bound DNA toward biological, physical, and chemical agents. Chem. Biol. Drug Des.67, 78–82 (2006).
48. Yang PH, Sun XS, Chiu JF et al.: Transferrin-mediated gold nanoparticle cellular uptake. Bioconjug. Chem. 16, 494–496 (2005).
49. Tartaj P, del Puerto Morales M, Veintemillas-Verdaguer S et al.: The preparation of magnetic nanoparticle for applications in biomedicine. J. Phys. D Appl. Phys. 36, R182–R197 (2003).
50. Zalipsky S: Functionalized poly(ethyleneglycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. 6, 150–165 (1995).
51. Sudimack J, Lee RJ: Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147–162 (2000).
52. Lubbe AS, Alexiou C, Bergemann C: Clinical applications of magnetic drug targeting. J. Surg. Res. 95, 200–206 (2001).
53. Nasongkla N, Bey E, Ren J et al.: Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano. Lett. 6, 2427–2430 (2006).
2. Roco MC: Nanotechnology: convergence with modern biology and medicine. Curr. Opin. Biotechnol. 14, 337–346 (2003).
3. Green JJ, Shi J, Chiu E et al.: Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug. Chem. 17, 1162–1169 (2006).
4. Torchilin VP: Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532–1555 (2006).
5. Kreuter J: Nanoparticles – a historical perspective. Int. J. Pharm. 331, 1–10 (2007).
6. Kreuter J: Nanoparticles as drug delivery systems. Encyclopedia Nanosci. Nanotechnol. 7, 161–180 (2004).
7. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318 (2001).
Presents the development of targeted and long-circulating nanomedicines.
8. Duguet E, Vasseur S, Mornet S et al.: Magnetic nanoparticles and their applications in medicine. Nanomed. 1, 157–168 (2006).
9. Torchilin VP: Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128–E147 (2007).
10. Singh S, Nalwa HS: Nanotechnology and health safety-toxicity and risk assessments of nanostructured materials on human health. J. Nanosci. Nanotechnol. 7, 3048–3070 (2007).
11. Allemann GE, Fessi H, Doelker E: Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22, 419–464 (2005).
12. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46, 149–168 (2001).
13. Hong S, Lerouell PR, Majoros IJ et al.: The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14, 107–115 (2007).
14. Brigger I, Dubernet C, Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631–651 (2002).
15. Steinhauser I, Spankuch B, Strebhardt K et al.: Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27, 4975–4983 (2006).
16. Tiefenauer LX, Kuhne G, Andres RY: Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 4, 347–352 (1993).
17. Hood JD, Bednarski M, Frausto R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002).
18. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phase display peptide libraries. Nature 380, 364–366 (1996).
19. Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542–546 (1997).
20. Shukla R, Thomas TP, Peters JL et al.: HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug. Chem. 17 1109–1115 (2006).
21. Sapra P, Allen TM: Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190–7194 (2002).
22. Cristoiu-Hapca A, Bossy-Nobs L, Buchegger F et al.: Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int. J Pharm. 331, 190–196 (2007).
23. Gartner S, Markovits P, Markovitz DM et al.: The role of mononuclear phagocytes in HTLV–III/LAV infection. Science 233, 215–219 (1986).
24. McCarthy TD, Karellas P, Henderson SA et al.: Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312–318 (2005).
25. Zhao H, Li J, Xi F et al.: Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA. FEBS Lett. 563, 241–245 (2004).
26. Begley DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharm. Ther. 104, 29–45 (2004).
27. Chen Y, Dalwadi G, Benson HAE: Drug delivery across the blood–brain barrier. Curr. Drug Deliv. 1, 361–376 (2004).
28. Allen DD, Lockman PR, Oyewumi MO et al.: Brain uptake of thiamine-coated nanoparticles. J.Control. Release 93, 271–282 (2003).
29. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37(1):13-25.
30. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32 (11):1959-72; PMID:22929442; http://dx.doi.org/ 10.1038/jcbfm.2012.126
31. Wagner, V., Dullaart, A., Bock, A.-K. & Zweck, A. The emerging nanomedicine landscape. Nat. Biotech. 24, 1211–1217 (2006).
32. Allemann E, Gurny R, Doelker E: Drug-loaded nanoparticles – preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39, 173–191 (1993).
33. Gref R, Minamitake Y, Peracchia MT et al.: Biodegradable long circulating nanospheres. Science 263, 1600–1603 (1994).
34. Labhasetwar V, Song C, Levy RJ: Nanoparticles drug delivery systems. Adv. Drug Deliv. Rev. 24, 63–85 (1997).
35. Swartz MA: The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50, 3–20 (2001).
36. Brannon-Peppas L: Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116, 1–9 (1995).
37. Castaldello A, Brocca-Cofano E, Voltan R40 et al.: DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 24, 5655–5669 (2006).
38. Mehnert W, Mader K: Solid lipid nanoparticles Production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165–196 (2001).
39. Venkateswarlu V, Manjunath K: Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95, 627–638 (2004).
40. Fahmy TM, Fong PM, Park Jet al.: Nanosystems for simultaneous imaging and drug delivery to T Cells. AAPS J. 9, E171–E180 (2007).
41. Li Y, Cheng Y, Xu T: Design, synthesis and potent pharmaceutical applications of glycodendrimers. Curr. Drug Discov. Technol. 4, 246–254 (2007).
42. Rosa Borges A, Schengrund CL: Dendrimers and antivirals: a review. Cur. Drug Targets Infect. Disord. 5, 247–254 (2005).
43. Wolinsky JB, Grinstaff MW: Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv.Drug Deliv. Rev. 60, 1037–1055 (2008).
44. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145–160 (2005).
45. Connor EE, Mwamuka J, Gole A et al.: Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1, 325–327 (2005).
46. Joshi HM, Bhumkar DR, Joshi K et al.: Gold nanoparticles as carrier for efficient transmucosal insulin delivery. Langmuir 22, 300–305 (2006).
47. Han G, Martin CT, Rotello VM: Stability of gold nanoparticle-bound DNA toward biological, physical, and chemical agents. Chem. Biol. Drug Des.67, 78–82 (2006).
48. Yang PH, Sun XS, Chiu JF et al.: Transferrin-mediated gold nanoparticle cellular uptake. Bioconjug. Chem. 16, 494–496 (2005).
49. Tartaj P, del Puerto Morales M, Veintemillas-Verdaguer S et al.: The preparation of magnetic nanoparticle for applications in biomedicine. J. Phys. D Appl. Phys. 36, R182–R197 (2003).
50. Zalipsky S: Functionalized poly(ethyleneglycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. 6, 150–165 (1995).
51. Sudimack J, Lee RJ: Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147–162 (2000).
52. Lubbe AS, Alexiou C, Bergemann C: Clinical applications of magnetic drug targeting. J. Surg. Res. 95, 200–206 (2001).
53. Nasongkla N, Bey E, Ren J et al.: Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano. Lett. 6, 2427–2430 (2006).
Published
30/04/2020
Statistics
152 Views | 121 Downloads
Citatons
How to Cite
[1]
K. K.Jayalakshimi, L. Lahari.sidde, K. K.Sailakshimi, and P. P.Sahithya, “A BRIEF REVIEW ON NANO PARTICLES TO TREAT VARIOUS DISORDERS”, Int J Indig Herb Drug, pp. 1-10, Apr. 2020.
Section
Review Articles
Copyright © Author(s) retain the copyright of this article.
.